Palisade Bio Seeks Shareholder Approval for Over 115% Potential Dilution and Large Director Equity Grants

summarizeSummary

Palisade Bio is asking shareholders to approve a 150 million share increase in authorized common stock and new equity incentive plans, collectively representing over 115% potential dilution. The company also seeks approval for large RSU grants to directors that exceed compensation limits, citing prior massive dilution.

check_boxKey Events

• Proposed Increase in Authorized Common Stock

  The company seeks to increase authorized common stock from 300 million to 450 million shares, adding 150 million shares. This represents a potential dilution of approximately 90% based on current outstanding shares.

• New Equity Incentive Plan Proposed

  Shareholders will vote on an Amended and Restated 2021 Equity Incentive Plan, which would authorize 42.26 million shares for issuance. This new pool represents approximately 25% dilution relative to current outstanding shares, though it eliminates an 'evergreen' feature.

• Significant Director Equity Grants Exceed Limits

  The company proposes one-time RSU grants totaling 2.68 million shares to non-employee directors, explicitly stating these grants exceed current and proposed compensation limits. These grants are valued at over $5.26 million at the current stock price.

• Context of Prior Massive Dilution

  The justification for the large director grants references a prior financing in October 2025 that resulted in approximately 1,854.5% dilution to pre-existing common stock, highlighting ongoing capital structure challenges.

auto_awesomeAnalysis

Palisade Bio has filed its definitive proxy statement for its upcoming annual meeting, seeking shareholder approval for several proposals that could lead to substantial dilution. The most significant proposal is to increase the authorized common stock by 150 million shares, from 300 million to 450 million. This represents a potential dilution of approximately 90% relative to the current 167.4 million outstanding shares. Additionally, the company is requesting approval for a new equity incentive plan with a pool of 42.26 million shares (approximately 25% of current outstanding) and an employee stock purchase plan with 0.84 million shares. Cumulatively, these proposals could result in over 115% potential dilution if all authorized shares and equity plan shares were issued. The filing also includes a proposal for significant RSU grants to non-employee directors, totaling 2.68 million shares (worth over $5.26 million at current prices), which explicitly exceed current and proposed compensation limits. These grants are justified by prior massive dilution from an October 2025 financing, raising concerns about governance and the company's capital management strategy.